electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update
17 janv. 2023 08h00 HE
|
electroCore, Inc.
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue growth of approximately 57% over full-year 2021Launched two new...
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
12 janv. 2023 08h30 HE
|
Odyssey Health, Inc
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
20 déc. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called...
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
19 déc. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...
electroCore Announces Issuance of Two New U.S. Patents
07 déc. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...
gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
18 nov. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has...
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
15 nov. 2022 08h00 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
14 nov. 2022 16h05 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
electroCore Announces Third Quarter 2022 Financial Results
03 nov. 2022 16h05 HE
|
electroCore, Inc.
Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) --...
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
01 nov. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United...